Sepsis is a life threatening condition that arises when the body’s response to infection harms its own tissues and organs. It can progress to septic shock, where severe circulatory and metabolic abnormalities lead to a high risk of death. Early recognition and rapid treatment are critical, because outcomes worsen sharply with delay.

Research highlights the complex interplay between the invading pathogen and the host immune system. Instead of a single linear process, sepsis involves a dynamic mix of excessive inflammation, immune suppression, coagulation disturbances and microcirculatory failure. This complexity explains why many therapies that looked promising in animals or early trials failed in larger studies.

Current management focuses on timely antibiotics, source control of infection, fluid resuscitation and vasopressors when needed. Studies show that bundles of coordinated interventions, applied early, reduce mortality. However, these bundles must be adapted to the individual, as both under treatment and over treatment can be harmful.

There is intense interest in identifying reliable biomarkers to diagnose sepsis earlier, distinguish it from non infectious inflammation and predict prognosis. Molecules such as procalcitonin and C reactive protein are widely used but imperfect. Genomic and transcriptomic signatures are being explored to define sepsis subtypes that may respond differently to specific therapies.

Organ support in intensive care, including mechanical ventilation and renal replacement therapy, remains central. Emerging research investigates immunomodulatory drugs, host directed therapies and precision medicine approaches to tailor treatment to each patient’s biological profile. Despite major advances, sepsis remains a leading cause of death worldwide, underscoring the need for better diagnostics, targeted therapies and preventive strategies.